Alamar Biosciences Inc ALMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
-
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
-
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
-
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
-
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
-
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
-
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Trading Information
- Previous Close Price
- $31.45
- Day Range
- $28.36–31.43
- 52-Week Range
- $18.85–39.61
- Bid/Ask
- $23.16 / $30.47
- Shares Outstanding
- 69.39M
- Market Cap
- $2.06B
- Volume/Avg
- 675,413 / 489,392
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.87
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.alamarbio.com
Valuation
|
Metric
|
ALMR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.59 |
Price/Sales | 14.87 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALMR
|
|---|---|
Quick Ratio | 9.67 |
Current Ratio | 11.85 |
Interest Coverage | −67.68 |
Quick Ratio
ALMR
Profitability
|
Metric
|
ALMR
|
|---|---|
Return on Assets (Normalized) | −18.38% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −78.94% |
Return on Assets
ALMR
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|hQgk%^^ | LOCK|k?^%t | $177B | |||
| Medtronic PLC
MDT
| LOCK|W!Yzm& | LOCK|$zT&< | $124B | |||
| Stryker Corp
SYK
| LOCK|#J^^Px#^ | LOCK|@@f | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|#l%Htq@ | LOCK|f@@s | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|J$&#yb@Q | LOCK|?>q>w | $52B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|k@$H?@ | LOCK|ng> | $32B | |||
| DexCom Inc
DXCM
| LOCK|@zq%$@> | LOCK|?n>x | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|^KB | LOCK|y@ | $26B | |||
| Steris PLC
STE
| LOCK|XzvM>pT | LOCK|##?kC | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|^PDPBN@w | LOCK|?^@ | $19B |
United States